

Contents

<i>Preface</i>	v
<i>Expanded contents</i>	ix
 SECTION I: GENERAL CONSIDERATIONS AND BIOCHEMICAL CONCEPTS	
1. Introduction to parenteral drug delivery	3
2. Molecular basis of targeted drug delivery	38
3. Bioconjugates	81
4. Chemical drug delivery	122
 SECTION II: CARRIER CONCEPTS IN DRUG DELIVERY	
5. Liposomes	173
6. Niosomes	249
7. Submicron emulsions	280
8. Multiple emulsions	303
9. Nanoparticles	331
10. Resealed erythrocytes	387
11. Microspheres	417
12. Magnetically modulated drug delivery	458
 SECTION III: SITE-SPECIFIC DRUG DELIVERY	
13. Drug delivery to brain	487
14. Drug delivery to tumour	512
15. Drug delivery to bone marrow	562
<i>Index</i>	587

Expanded Contents

SECTION I General Considerations & Biochemical Concepts

1. Introduction to Parenteral Drug Delivery 3-37

Introduction	3
Liposomes	7
Liposomes in intracellular infections	9
Liposomes in tumour therapy	11
Other liposome applications	12
Niosomes	12
Nanoparticles and microspheres	13
Nanoparticles in chemotherapy	14
Avoidance of multidrug resistance	14
Adjuvant effect for vaccines	15
Solid lipid nanoparticles	15
Hydrogel nanoparticles	16
Nanocrystals and nano-suspensions	16
Microparticles	17
Long circulating microparticles	17
Specialized emulsions	18
Multiple emulsions	18
Emulsome™	19
Long circulatory emulsions	19
Resealed erythrocytes	20
Supramolecular biovectors	21
Orientation, organization and function	22
Chylomicrons	22
Lipoproteins	23
Extravasation of lipoproteins for cellular interaction	23
Cyclodextrins	23
Prodrugs	24
Antibody directed enzyme prodrug therapy (ADEPT)	25
Polymeric prodrugs (polymer-drug conjugates)	26
Biotin-avidin conjugates	27
Polymeric micelles	27
Aquasomes	28
Dendrimers	28
Implant systems	30
Systems for non-invasive systemic administration	33

Conclusion	33
References	34

2. Molecular Basis of Targeted Drug Delivery 38-80

Introduction	38
The concepts of targeting	39
Rationale of drug targeting	39
Carriers	40
Levels of drug targeting	42
Cellular biochemistry and molecular events in drug targeting	47
Cell surface biochemistry and molecular targets	47
Molecular targets for cellular targeting	47
Receptor as delivery ports	49
Ligands as delivery and targeting tools	50
Ligand driven receptor mediated drug delivery	51
Cellular machinery that drive receptor mediated bioevents	51
Intracellular processing and disposition of drug-carrier composites	55
Receptor mediated drug delivery using biochemical and molecular ligands	60
Carbohydrate specific (lectin) receptors	61
Asialo-glycoprotein receptor	62
Mannose, mannosyl-fucosyl (MF) receptors	64
Lymphocyte homing receptors	66
Cell surface receptor expressed for immunoregulatory molecules	66
Fc receptors	66
Complement receptors	67
Interleukin receptors	68
Interferons	70
MHC and CD glycoproteins	70
Receptors for endogenous proteins and macromolecules	70
Tumour/viral cell surface biochemistry and ligand mediated targeting strategies	75
Altered/over expression of cell specific receptors	76
Expression of vasoactive and angiogenic epitopes on tumour vascular endothelium	78
Future perspectives	79
References	79

3. Bioconjugates 81-121

Introduction	81
Bioconjugation techniques	81
Covalent conjugation	82
Non-covalent conjugation	85
Classes of bioconjugates	87
Characterization of bioconjugates	88
Applications of bioconjugates	89
Bioconjugates in drug delivery and targeting	89
Antibody conjugates (immunoconjugates)	89
Antibody conjugated delivery systems	90
Antibody enzyme conjugates	91
Bispecific antibodies	92

Antibody conjugated liposomes (Immunoliposomes)	93
Haptenated conjugates of liposomes	96
Antibodies conjugates developed against angiogenic peptides	96
Bioconjugates of immunotoxins/ chimeric proteins	98
CD4 bioconjugates	99
Recombinant CD4 toxin conjugates	100
Liposome conjugated CD4 fragments	100
Transferrin based bioconjugates	100
Transferrin-drug conjugates	102
Transferrin-liposome conjugates	102
Anti-transferrin antibody-conjugates	103
Folic acid (folate) based bioconjugates	105
Insulin based bioconjugates	107
Bioconjugates with cytokines	108
Glycoconjugates	110
Neoglycoprotein-drug conjugates	110
Neoglycoprotein-liposome conjugates	112
Poly ethylene glycol (PEG) conjugates	114
PEG conjugates with peptides and proteins (mainly enzymes)	114
PEG conjugates with low molecular weight drugs	115
PEG conjugates with lipids	115
PEG conjugates with biological macromolecules	116
Poly-L-lysine conjugates	116
Future perspectives	118
References	118

4. Chemical Drug Delivery

122-169

Introduction	122
Prodrug and chemical delivery systems	123
Eye as a target organ	123
Chemical delivery systems for eye	124
Skin	125
CDS for kidney	127
Lung as a target organ	127
Colon targeting	128
CDS for liver targeting	129
Lymphatic targeting	129
Brain as a target organ for CDS	137
Tumour targeting by CDS	154
Antibody and enzyme based tumour targeting	157
Soft drug approach	160
Membrane transporters as targeting site	163
Peptide transporter associated prodrug therapy	164
Conclusion	164
References	165

SECTION II

Carrier Concepts in Drug Delivery

5. Liposomes	173-248
Introduction	173
Mechanism(s) of liposome formation	174
Rigidization of fluid phase vesicles with cholesterol	176
Molecular geometry and liposome formation (Israelachvili hypothesis)	180
Vesicle formation in living cells	180
Classification of liposomes	181
Methods of liposome preparation and drug loading	181
Passive loading techniques	182
Mechanical dispersion methods of passive loading	182
Thin film hydration using hand shaking (MLVs) and non-shaking methods (ULVs)	182
Pro-liposomes	183
Mechanical treatment of MLVs	183
Dried-reconstituted vesicles (DRVs)	186
Freeze thaw sonication (FTS) method	187
Liposomes from preformed vesicles	188
Solvent dispersion methods of passive loading	188
Ethanol injection	189
Ether injection	189
Rapid solvent exchange vesicles (RSEVs)	190
De-emulsification methods	190
Detergent depletion (removal) methods of passive loading	191
Dialysis	193
Column chromatography	193
Detergent adsorption using bio-beads	193
Remote (active) loading	193
Microencapsulation or locus of drugs in liposomes	195
Lipophilic transformation of drugs: Pharmacosomes	196
Removal of untrapped drug from liposomes	196
Characterization of liposomes	196
Vesicle shape and lamellarity	197
Vesicle size and size distribution	198
Surface charge	201
Encapsulation efficiency and trapped volume	201
Phase response and transitional behaviour	203
Vesicle fusion measurements	203
Chemical characterization of liposomes	204
Stability of liposomes	205
Stability <i>in vitro</i>	205
Long term and accelerated stability	207
Stability after systemic administration	208
Stability <i>in vivo</i> after oral administration	209
Interactions of liposomal drug delivery systems with cells	209
Liposomal pharmacokinetics	210
Pharmacokinetics of liposomes after intravenous administration	210
Pharmacokinetics of release of liposomal contents in tissues	213
Pharmacokinetics of long-circulatory liposomes for tumour targeting/localization	213

Commercial development and scale up	215
Freeze-drying and cryoprotection/ lyoprotection of liposomal products	215
Commercial manufacturing of liposomal drugs	216
Therapeutic applications of liposomes	217
Liposomes as drug delivery vehicle	217
Liposomes in anti-microbial, anti-fungal (lung therapeutics) anti-viral (anti-HIV) therapy	221
Liposomes in tumour therapy	224
Liposomes in gene therapy	228
Liposomes in antisense oligonucleotide therapy	234
Immunological applications of liposomes	235
Liposomes in dermatology and cosmetology	239
Liposomes as radiopharmaceutical and radiodiagnostic carriers	241
Liposomes as red cell substitutes and artificial RBCs	242
Miscellaneous applications	242
Conclusion	243
References	243

6. Niosomes 249-279

Introduction	249
Physicochemical aspects of non-ionic surfactant vesicles	251
Structural components and niosomes bilayer	251
Other structural components	253
Methods of preparation	258
Ether injection	259
Hand shaking method	259
Sonication	259
Reverse phase evaporation	259
Aqueous dispersion	259
Extrusion	259
Separation of free drug	260
Characterization of niosomes	260
Size, shape and morphology	260
Entrapment efficiency	261
Encapsulation efficiency and solute release rates	262
Vesicle surface charge	264
Stability of niosomes	265
Stability in buffer	265
Stability in hypertonic media	265
Stability in hypotonic media	265
Stability <i>in vivo</i>	265
Rheological properties of niosomal dispersion	266
Solute release profile form niosomal formulations	266
Colloidal properties of niosomal dispersion	267
Discomes	267
NSVs reversed vesicles	269
Non-ionic surfactant vesicle-in-water-in-oil (V/W/O) systems	269
Non-ionic surfactant based organogels	270
Polymer coated non-ionic surfactant vesicles	270
Proniosomes	270

Non-ionic surfactant vesicles and their therapeutic potential	271
Niosomes for the treatment of leishmaniasis	271
Niosomes in oncology	272
Niosomes as immunological adjuvant	274
Nonionic surfactants and oral drug delivery	274
Niosomes for transdermal drug delivery	275
Niosomes and diagnostic imaging	276
References	277

7. Submicron Emulsions 280-302

Introduction	280
Submicron lipid emulsions	281
Microemulsions	282
Basic aspects of microemulsions	282
Microemulsion formation and phase behaviour	284
Phase behaviour	285
Theoretical aspects of the preparation of microemulsions	286
Single surfactant systems	288
Temperature-insensitive microemulsions	289
Characterization of microemulsions	291
Phase behaviour studies	292
Scattering techniques for microemulsions characterization	292
Nuclear magnetic resonance studies	293
Electron microscopic studies	293
Interfacial tension, electrical conductivity and viscosity measurements	293
Advantages of microemulsion-based systems	294
Applications of microemulsions	294
Oral drug delivery	295
Topical drug delivery	295
Ocular and pulmonary delivery	297
Solubilization of drugs in microemulsions	297
Parenteral administration	297
Perfluoro microemulsions	298
Microemulsions in biotechnology	298
Solid colloidal systems prepared from microemulsions	299
From W/O microemulsions	299
From O/W microemulsions	300
Self emulsifying drug delivery systems (SEDDs)	300
References	300

8. Multiple Emulsion 303-330

Introduction	303
Principles of liquid surfactant membrane emulsion	304
Preparation aspects of multiple emulsion	304
A static aspect of multiple emulsion formation	304
Methods of preparation	306
Two step emulsification (double emulsification)	306
Phase inversion technique (one step technique)	306

Membrane emulsification technique	307
<i>In vitro</i> characterization	308
Average globule size and size distribution	308
Area of interfaces	308
Number of globules	309
Rheological evaluation	309
Zeta potential	309
Percent drug entrapment	309
<i>In vitro</i> drug release	309
<i>In vitro</i> stability studies	309
Stability of multiple emulsions	310
Breakdown pathways	316
Factors affecting stability	311
Methods to stabilize multiple emulsion	312
Drug release mechanisms and models	314
Fusion of unionized drug (hydrophobic species) through	
-the oil layer (diffusion rate model)	314
Planer sheet model	315
Micelle formation model/oil thinning or rupture model	316
Carrier oriented transport	316
Carrier oriented transport	316
<i>In vivo</i> fate of multiple emulsions	317
Applications in therapeutics and cosmetics	319
Controlled and sustained drug delivery	319
Targeting of bioactives	322
Vaccine adjuvant	322
Multiple emulsion for local immunosuppression	323
Absorption enhancement through gastrointestinal tract	323
Delivery of proteins and peptides	323
Haemoglobin multiple emulsion as an oxygen delivery system	324
Enzyme immobilization	324
Microencapsulation technology using multiple emulsion as an intermediate step	325
Cosmetics and health care	327
Miscellaneous applications	328
Future perspectives	328
References	328

9. Nanoparticles

331-386

Introduction	331
Natural hydrophilic polymers	332
Synthetic hydrophobic polymers	332
Preparation techniques of nanoparticles	332
Nanoparticle preparation by cross linking of amphiphilic macromolecule	333
Nanoparticle preparation using polymerization based methods	336
Nanoparticle preparation using polymer precipitation methods	342
Novel nanoparticulate systems	346
Solid lipid nanoparticles	346
SLN vs other colloidal drug carriers	347
Synthetic nanoparticles using microemulsions as nano-size reactors	348
Copolymerized peptide nanoparticles (CPP)	350

Hydrogel nanoparticles	350
Nanocrystals and Nanosuspensions	351
Drug loading and <i>in vitro</i> release process	351
<i>In vitro</i> release profile of lipophilic drugs	352
<i>In vitro</i> release profile of hydrophilic drugs	353
Pharmaceutical aspects of nanoparticles	353
Purification of nanoparticles	353
Freeze drying of nanoparticles	355
Sterilization of nanoparticles	355
Characterization of nanoparticles	356
Size and morphology	356
Specific surface	357
Surface charge and electrophoretic mobility	357
Surface hydrophobicity	358
Density	358
Molecular weight measurements of nanoparticles	358
Nanoparticle recovery and drug incorporation efficiency	358
<i>In vitro</i> release	359
<i>In vivo</i> fate and biodistribution of nanoparticles	359
Surface engineering of nanoparticles	361
Steric stabilized (stealth) nanoparticles	361
Nanoparticles for bioadhesion	365
Biomimetic nanoparticles	366
Magnetic nanoparticles	366
Nanoparticles coated with antibodies	367
Therapeutic applications of nanoparticles	368
Intracellular targeting	368
Nanoparticle in chemotherapy	371
Adjuvant effect for vaccine	372
Nanoparticles for peroral administration of protein and peptides	373
Nanoparticles in intraarterial applications	374
Nanoparticles for ocular delivery	374
Nanoparticles for brain delivery	375
Nanoparticles for DNA delivery	376
Nanoparticles for oligonucleotide delivery	377
Nanoparticle in lymph targeting	379
Functionalized nanoparticles: a new dimension in innovative research	379
Conclusion	381
References	381

10. Resealed Erythrocytes

387-416

Introduction	387
Drug carrying potential of erythrocytes	387
Basic features of erythrocytes	388
Composition of erythrocytes	388
Electrolyte composition of erythrocytes	388
Haematocrit value and erythrocyte sedimentation rate	389
Source, fractionation and isolation of erythrocytes	389
Methods of drug loading	390
Hypotonic haemolysis and isotonic resealing methods	390

Electro-insertion or electroencapsulation	394
Loading by electric cell fusion	395
Entrapment by endocytosis	396
Loading by chemical perturbation of membrane (drug mediated loading)	396
Loading by lipid fusion	397
<i>In vitro</i> characterization	397
Drug content	397
<i>In vitro</i> drug and haemoglobin release	397
Osmotic fragility	398
Osmotic shock	398
Turbulence shock	399
Morphology and percent cellular recovery	399
Different forms of drug loaded red blood cells	399
Shelf and storage stability of resealed erythrocytes	400
<i>In vivo</i> survival and immunological consequences	400
Influence of membranolytic and membranotropic substrates	401
Biomedical applications of resealed erythrocytes	401
Erythrocytes as drug/enzyme carriers	401
Drug targeting	402
Targeting to sites other than RES rich organs	405
Erythrocytes as circulating bioreactors	407
Macrophage activation	409
Thrombolytic therapy	409
Delivery of interleukins	410
Oxygen deficiency therapy	410
Resealed erythrocytes in cell biological applications	411
Cell biological applications	411
Novel systems	413
Nanoerythroosomes	413
Erythroosomes	413
Future prospectives	413
References	413

11. Microspheres

417-457

Introduction	417
Material(s) used	418
Prerequisites for ideal microparticulate carriers	418
General methods of preparation	419
Single emulsion technique	419
Double emulsion techniques	420
Polymerization techniques	420
Phase separation coacervation technique	423
Spray drying and spray congealing	424
Solvent extraction	424
Loading of drug	425
Drug release kinetics	425
Reservoir type system	426
Matrix type system	426
Polymeric microspheres	427

Albumin microspheres	427
Gelatin microspheres	428
Starch microspheres	429
Dextran microspheres	430
Poly lactide and poly glycolide microspheres	431
Polyanhydride microspheres	432
Polyphosphazene microspheres	433
Chitosan microspheres	434
Carrageenan microspheres	436
Alginate microspheres	436
Poly(alkyl cyanoacrylate) microspheres	438
Poly acrolein microspheres	439
Fate of microspheres in body	439
Characterization	441
Particle size and shape	442
Electron spectroscopy for chemical analysis	442
Attenuated total reflectance fourier transform-infrared spectroscopy	442
Density determination	442
Isoelectric point	442
Surface carboxylic acid residue	442
Surface amino acid residue	443
Capture efficiency	443
Release studies	443
Angle of contact	444
Applications	444
Microspheres in vaccine delivery	444
Microspheres and immune system	447
Targeting using microparticulate carriers	447
Magnetic microspheres	449
Monoclonal antibodies mediated microspheres targeting-immunomicrospheres	450
Chemoembolization	451
Imaging	453
Microsponges: Topical porous microspheres	453
Surface modified microspheres	453
Future perspective	454
References	454

12. Magnetically Modulated Drug Delivery

458-483

Introduction	458
History of magnetic guidance	459
Magnatically modulated microcarriers	459
Magnetic microspheres	460
Magnetite (Fe_3O_4)	463
Biodistribution and tissue concentration of microspheres	465
Carrier localization	465
Biomodulators	466
Magnetic nanoparticles	467
Magnetic liposomes	471
Magnetic resealed erythrocytes	476
Magnetic emulsions	478

Magnetic carriers in protein immobilization	478
Magnetically modulated systems and devices	478
System parameters	479
Mechanism	479
<i>In vivo</i> experiments	480
Magnetically modulated, implantable, hemispheric drug delivery device	480
Magnetic systems in contraceptive drug delivery	480
Magnetically programmable infusion pumps	480
Conclusion	481
References	482

SECTION III

Site-Specific Drug Delivery

13. Drug Delivery to Brain 487-511

Introduction	487
The fluid-brain barrier	488
Cell biology and anatomy of BBB	488
Multiple function of BBB	491
The BBB as an active pump	491
The BBB as a metabolic barrier	494
Regulation of BBB function	494
Limitation in brain uptake of drugs	494
Transport through BBB	494
Carrier mediated transport system	495
Receptor mediated transcytosis (RMT)	495
Absorptive mediated transcytosis (AMT)	498
Factors affecting drug permeation through BBB	499
Brain drug delivery strategies	500
Neurosurgical or invasive strategies	500
Physiologic based strategies	501
Pharmacologic strategies	503
Small colloidal particles for brain targeting	507
Nanoparticles for brain targeting	507
Liposomes for brain targeting	508
Monocytes for brain targeting	508
Future prospects	508
References	509

14. Drug Delivery to Tumour 512-561

Introduction	512
Tumour vasculature vs normal vasculature	512
How tumour develops	513
Vascularization and localization of drug carriers in tumours	515
Barriers offered by tumour vasculature	516
Molecular targets for tumour therapy	518
Surface determinants on the tumour sites	519
Folate, transferrin, fucose and lipoproteins as over-expressed tumour receptors	519
Epitopes on tumour vascular endothelium for selective drug delivery	520

Angiogenesis as a target	520
Immunotherapy of tumour	521
Antibodies as targeting tools	521
Recombinant antibodies	521
Antibody enzyme conjugates	522
Bispecific antibodies	523
Bioconjugates of immunotoxins/chimeric proteins	524
Problems of delivery of monoclonal antibodies	525
Tumour antigens and vaccines	526
Cytokines	527
Interleukins	527
Molecular approaches in tumour therapy	528
Vasoactive and angiogenic peptides	528
Fas receptor-Fas ligand systems	529
Cell adhesion molecules	530
Altered/over expression of cell specific receptors	535
Gene therapy	538
Molecular targets (defective genes) for tumour therapy	539
Non-viral gene delivery for p53	540
Targeted, non-viral gene delivery for tumour gene therapy	541
Suicide gene therapy	541
Targeting delivery of genes using Mabs; immunogene approach	542
Antisense oligonucleotides as genetic medicines	542
Tumour targeting and drug delivery systems	542
Site specific drug delivery	543
Multi drug resistance	544
Role of drug carriers in overcoming multi-drug resistance	545
Problems associated with tumour targeted delivery systems	546
Liposomes in tumour therapy	547
Micro/nanoparticles in chemotherapy	554
Future perspectives	556
Vascular targeting with phage peptide libraries	556
Application of peptide nucleic acid in tumour therapy	556
Polyethylene glycol modifications in tumour targeting	556
Local delivery of anti-neoplastic agents using biodegradable polymers	557
Others	557
References	557

15. Drug Delivery to Bone Marrow

562-585

Introduction	562
Stem cells and progenitor cells of bone marrow	562
Anatomy and physiology of bone marrow	563
Bone marrow transplantation	565
Types of Transplants	566
Bone marrow targeting	566
Reduction in the haemopoietic damage during chemo or radiotherapy	567
Hereditary and congenital disorders	567
Bone marrow related diseases	567
Drugs that have catastrophic and unpredicted action on haematopoiesis	568
Distinct physiological functions of the components of the bone marrow	568

Bone marrow targets for drug delivery	568
Reticuloendothelial system (RES) of bone marrow for passive -and intravascular targeting	568
Sinusoidal capillaries for extravascular targeting	569
Haemopoietic cytokines as homing molecules	570
Carbohydrate determinants as possible homing ligands	570
Adhesion molecules as possible homing ligands	571
Colloidal carriers for bone marrow targeting	571
Colloidal particles	572
Liposomes	575
Purging of bone marrow with liposomes	578
Monoclonal antibodies and immunoconjugates for <i>ex vivo</i> drug delivery	580
Diagnostic imaging of bone marrow using radiolabelled particulate	581
Bone marrow transplantation using cytostatic drug loaded carriers	583
Antigen presentation to bone marrow	583
Future trends	584
References	

Index	586
--------------	------------